A new metabolic therapy for treating Alzheimer’s Disease

Project specs

Format

3D

Contact

Shawn Ritchie

Country

Canada

Funding agency

Funded by GraySpace Therapeutics Inc

Length

01:36

Summary

This video highlights the mechanism of action of GraySpace’s patented plasmalogen precursors for treating and preventing neurodegenerative diseases including Alzheimer’s disease (AD). Plasmalogen deficiency results in impaired neurotransmission, which is believed to underly the development and progression of AD. We believe that plasmalogen replacement will be an absolute requirement for the successful treatment of Alzheimer’s disease.